Clinical trials: Pneumonia
Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
To evaluate the safety, efficacy and pharmacokinetics of nilotinib over time in the Ph+ chronic myelogenous leukemia (CML) in pediatric patients (from 1 to <18 years).
- Trial name
- DIALOG (NCT01844765)
- Testing
- nilotinib
- Where
- 36 sites in United States, France and 11 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Cytokine Storm, COVID-19
Early Treatment of Cytokine Storm Syndrome in Covid-19
This proposal addresses the problem of preventing the very high mortality and morbidity associated with the development of Cytokine Storm Syndrome (CSS) associated respiratory failure in Covid-19 infection.
- Trial name
- NCT04362111
- Testing
- Anakinra, Normal saline
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Alabama at Birmingham
Rheumatoid Arthritis, Interstitial Pneumonia
Rituximab in Rheumatoid Arthritis Lung Disease
This study will examine the course of patients with progressive rheumatoid arthritis associated interstitial lung disease (RA-ILD) treated with rituximab for safety and progression-free survival at 48 weeks.
- Trial name
- NCT00578565
- Testing
- Rituximab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Eric Matteson
SARS-CoV2 Infection
Culturally-Targeted COVID-19 Communication and SARS-CoV-2 Antibody Testing Evaluation and Uptake
This disparities-focused study seeks to evaluate communication strategies for better encouraging understanding and uptake of salivary SARS-CoV-2 antibody testing among African Americans residing in Flint, Michigan.
- Trial name
- NCT04957082
- Testing
- Culturally Targeted SARS-CoV-2 Communication, General SARS-CoV-2 Communication
- Where
- United States
- Volunteers
- 666 people, healthy volunteers welcome
- Sponsor
- Michigan State University
COVID-19
A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults
This study is designed to evaluate three dose levels of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) (COVID-HIGIV) for safety and pharmacokinetics (PK) in healthy adults.
- Trial name
- NCT04661839
- Testing
- COVID-HIGIV
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Cystic Fibrosis, Pneumonia
Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children
This study will determine the concentrations of the antibiotic meropenem when administered as a 3 hour prolonged infusion in children with cystic fibrosis who are hospitalized with an acute pulmonary exacerbation.
- Conditions
- Cystic Fibrosis, Pneumonia, Pseudomonas Aeruginosa Infection
- Trial name
- NCT01429259
- Testing
- meropenem
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Joseph Kuti
GVHD, Chronic
Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)
This is a phase 2, open-label, multicenter trial to evaluate the efficacy and safety of BN101 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least First Line of systemic therapy.
- Trial name
- NCT04930562
- Testing
- BN101
- Where
- 7 sites in China
- Volunteers
- 30 people
- Sponsor
- BioNova Pharmaceuticals (Shanghai) LTD.
COVID-19
Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection
The purpose of this study is to find out whether the study drug tocilizumab is an effective treatment for COVID-19 infection.
- Trial name
- NCT04377659
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
COVID-19, Coronavirus Infection
A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection
This is a Phase II interventional study testing whether treatment with hydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent symptoms of COVID-19
- Conditions
- COVID-19, Coronavirus Infection, Sars-CoV2, Corona Virus Infection
- Trial name
- HELPCOVID-19 (NCT04335084)
- Testing
- Hydroxychloroquine, Vitamin C, Vitamin D
- Where
- United States
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- ProgenaBiome
Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC
13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India
This study is to describe the safety and immunogenicity of 13vPnC in Indian adults 50 to 65 years of age and in Indian children 6 to 17 years of age.
- Trial name
- NCT02034877
- Testing
- 13-valent Pneumococcal conjugate vaccine, Blood sample collection
- Where
- 16 sites in India
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Pfizer
Sars-CoV2, Acute Respiratory Distress Syndrome
Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)
*At this time, we are only enrolling at Houston Methodist Hospital (HMH)/Baylor College of Medicine (BCM) and are not shipping cells outside of BCM/HMH.* This is a study for patients who have respiratory infection caused by…
- Conditions
- Sars-CoV2, Acute Respiratory Distress Syndrome, COVID-19
- Trial name
- NCT04345601
- Testing
- Mesenchymal Stromal Cells, Supportive Care
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Baylor College of Medicine
COVID-19 Pneumonia, Vascular Complications
Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19
Brief Summary: The goal here is to evaluate dipyridamole in treating respiratory tract infection and circulatory dysfunction due to SARS-CoV-2 coronavirus in hospitalized CVID-19 patients.
- Trial name
- TOLD (NCT04424901)
- Testing
- Dipyridamole Tablets
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- UConn Health
COVID-19
Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults
This is a multicenter, US-only, phase 1, open-label, dose escalation, non-randomized study of the safety, tolerability, and immunogenicity of investigational ChAd and SAM SARS-CoV-2 vaccines in healthy adult subjects.
- Trial name
- NCT04776317
- Testing
- ChAdV68-S, ChAdV68-S-TCE, SAM-LNP-S
- Where
- 4 sites in United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Solid Organ Transplant Recipients, Autoimmune Diseases
Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies
DESIGN Observational epidemiological study AIMS - To determine: 1. The proportion of immunosuppressed people who have detectable SARS-CoV-2 antibodies following a primary vaccine course (3 doses), and the demographic, disease…
- Conditions
- Solid Organ Transplant Recipients, Autoimmune Diseases, Haematological Malignancies
- Trial name
- MELODY (NCT05148806)
- Testing
- self-administered lateral flow assays
- Where
- 4 sites in United Kingdom
- Volunteers
- 28,411 people
- Sponsor
- Imperial College London
Covid19
KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers
This is an First In Human (FIH), observer-blinded, randomized, placebo-controlled, parallel group study to evaluate the safety and immunogenicity of KBP-COVID-19 plus CPG adjuvant vaccine in healthy adult subjects in 2 age…
- Trial name
- NCT04473690
- Testing
- Low Dose of KBP-COVID-19, High Dose of KBP-COVID-19
- Where
- 8 sites in United States, Canada
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- KBio Inc
COVID-19, COVID
Early CPAP in COVID-19 Confirmed or Suspected Patients
There is surge in COVID infected patients in New York City with a shortage of hospital beds, ICU beds and ventilators. Strategies to reduce the need for all of the above are immediately needed.
- Conditions
- COVID-19, COVID, Coronavirus
- Trial name
- PAP-COVID (NCT04390191)
- Testing
- Continuous Positive Airway Pressure
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Ischemic Heart Disease, Hopelessness
Reducing Hopelessness Through Improved Physical Activity in Adults With Heart Disease: With COVID-19 Considerations
After a 30-year decline, heart disease is projected to increase up to 18% by 2030. Participation rates in cardiac rehabilitation remain extremely low and hopeless individuals are less likely to participate.
- Conditions
- Ischemic Heart Disease, Hopelessness, Physical Activity, Motivation
- Trial name
- Heart Up! (NCT03907891)
- Testing
- Motivational social support from nurse, Motivational social support from nurse with additional support from significant other, Attention control
- Where
- United States
- Volunteers
- 224 people
- Sponsor
- University of Illinois Chicago
Covid19, Sequelae of; Infection
Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19
The study will assess whether Niagen, a safe dietary supplement, improves recovery of COVID-19 related symptoms in individuals who were infected at least 2 months prior to study entry ("Long-COVID" "Long-haulers").
- Conditions
- Covid19, Sequelae of; Infection, Cognitive Symptom
- Trial name
- NCT04809974
- Testing
- Niagen
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Massachusetts General Hospital
COVID-19
Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV).
This is a single-blind, randomised controlled clinical trial to determine the reactogenicity and immunogenicity of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) vaccines (Pfizer-BioNTech or Moderna) as booster dose…
- Trial name
- MIACoV (NCT05228730)
- Testing
- Tozinameran - Standard dose, Tozinameran - fractional dose, Elasomeran - standard dose
- Where
- Australia
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
End Stage Kidney Disease
Phenotyping Seroconversion Following Vaccination Against COVID-19 in Patients on Haemodialysis Study
Patients on haemodialysis are at higher risk of getting a severe form of COVID-19 if they become infected. Vaccinations are soon to arrive and offer great hope of controlling the current pandemic.
- Trial name
- NCT04815850
- Where
- United Kingdom
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- University of Leicester
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.